# EDGAR Filing Document

**Accession Number:** 0001622057
**File Stem:** 0001477932-23-000541
**Filing Date:** 2023-1
**Character Count:** 6751
**Document Hash:** 643d302375c7b42b6c087f6960172b2e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-23-000541.hdr.sgml**: 20230126

**ACCESSION NUMBER**: 0001477932-23-000541

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230125

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230126

**DATE AS OF CHANGE**: 20230125

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nascent Biotech Inc.
- **CENTRAL INDEX KEY:** 0001622057
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 450612715
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55299
- **FILM NUMBER:** 23553441

**BUSINESS ADDRESS:**
- **STREET 1:** 631 US HWY 1, SUITE 407
- **CITY:** NORTH PALM BEACH
- **STATE:** FL
- **ZIP:** 33408
- **BUSINESS PHONE:** 612-961-5656

**MAIL ADDRESS:**
- **STREET 1:** 631 US HWY 1, SUITE 407
- **CITY:** NORTH PALM BEACH
- **STATE:** FL
- **ZIP:** 33408

?xml version="1.0" encoding="utf-8"?nbio_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

**<u>January 25, 2023</u>**

---

| |
|:---|
| **NASCENT BIOTECH, INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Nevada** | **000-55299** | **45-0612715** |
| (State or other jurisdiction <br>of incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **631 US Hwy 1, Suite 407, North Palm Beach, FL**  | **33408** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code **<u>(612) 961-5656</u>**

**<u>N/A</u>**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01. Other Events**

Nascent Biotech, Inc. (OTCQB: NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company developing monoclonal antibodies that target various cancer types, issued a press release on January 25, 2023 announcing the completion of the dosing period of its Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for brain cancer.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

**ITEM 9.01. Financial Statements and Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1\*](nbio_ex991.htm) | [Press Release, dated January 25, 2023](nbio_ex991.htm) |
| 104\* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

---

\*Furnished herewith

2<br>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| |
|:---|
| **NASCENT BIOTECH, INC.** |
| */s/ Lowell Holden* |
| Lowell Holden<br>CFO |
| Date: January 25, 2023  |

---

3<br>

## Exhibit 99.1

&nbsp;&nbsp;&nbsp;&nbsp;**EXHIBIT 99.1**

**Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial**

NORTH PALM BEACH, FL January 25, 2023 / -

Nascent Biotech, Inc. (OTCQB: NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies that target various cancer types, announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for Brain Cancer.

The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the "FDA") for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab.

PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.

**About Nascent Biotech**

Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available.

For further information please visit our website www.nascentbiotech.com.

Safe Harbor: Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

**Corporate Contact**

Sean Carrick \| President \| CEO \| Nascent Biotech, Inc.

772.713.0541 Cell \| <u>sean.carrick@nascentbiotech.com</u> 

**Public Relations**

EDM Media, LLC

<u>https://edm.media</u>

**SOURCE:** Nascent Biotech Inc.